Lupin sells Japan arm to Unison for Rs 3,702 cr, exits generic business

The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India

Pharma major Lupin has divested its entire stake in its Japanese subsidiary, Kyowa Pharmaceutical Industry Co Ltd, to private equity firm Unison for an enterprise value of Japanese 57,361 million yen (Rs 3,702.4 crore). With this deal, Lupin has exited the generic pharmaceuticals business in Japan. However, it will continue to pursue opportunities in biosimialars and the complex generic space in that country through partnerships.

Lupin claimed it made four-and-a half times its initial investments in Japan through this deal and that it enjoyed the 'golden age of generics' in that country.

Lupin's subsidiary Nanomi B V, which holds a